Ionis Pharmaceuticals Competitors and Similar CompaniesClear all

Ionis Pharmaceuticals's competitors and similar companies include Lannett, Intellia Therapeutics, Ultragenyx, Bluebird Bio, Sarepta Therapeutics, Reata Pharmaceuticals, Arrowhead Pharmaceuticals and Alnylam Pharmaceuticals.
Ionis Pharmaceuticals
Ionis Pharmaceuticals
Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.
Lannett
Lannett
Lannett is a company that specializes in pharmaceutical product families.
Intellia Therapeutics
Intellia Therapeutics
Intellia is developing therapeutic products to help people with genetic diseases.
Ultragenyx
Ultragenyx
Ultragenyx Pharmaceutical is a company that develops therapies for rare genetic diseases.
Bluebird Bio
Bluebird Bio
Bluebird Bio is a developer of gene therapies for severe genetic diseases.
Sarepta Therapeutics
Sarepta Therapeutics
Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases.
Reata Pharmaceuticals
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.
Founding Date
Founding Date
1989
Founding Date
1942
Founding Date
2014
Founding Date
2010
Founding Date
1992
Founding Date
1980
Founding Date
2002
Founding Date
2004
Founding Date
2002
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Carlsbad, US HQ
Locations
Trevose, US HQ
Philadelphia, US
Locations
Cambridge, US HQ
Locations
Novato, US HQ
Buenos Aires, AR
São Paulo, BR
Bogotá, CO
Paris, FR
Berlin, DE
Tokyo, JP
see more
Locations
Somerville, US HQ
Locations
Cambridge, US HQ
Dublin, IE
Zug, CH
Providence, US
Locations
Plano, US HQ
Irving, US
Plano, US
Locations
Pasadena, US HQ
Madison, US
San Diego, US
Locations
Cambridge, US HQ
Paris, FR
Milan, IT
Tokyo, JP
Amsterdam, NL
Stockholm, SE
Zug, CH
see more
Employees
Employees
79621% increase
Employees
56031% decrease
Employees
27028% increase
Employees
1,31117% increase
Employees
32338% decrease
Employees
1,31413% increase
Employees
3217% decrease
Employees
13416% increase
Employees
1,32324% increase
Valuation ($)
Valuation ($)
5.9 b
Valuation ($)
7.4 m
Valuation ($)
2.4 b
Valuation ($)
3.2 b
Valuation ($)
192.7 m
Valuation ($)
11.8 b
Valuation ($)
6.6 b
Valuation ($)
3.3 b
Valuation ($)
19.4 b
Twitter followers
Twitter followers
4.4 k
Twitter followers
N/A
Twitter followers
9.3 k
Twitter followers
N/A
Twitter followers
10.6 k
Twitter followers
5 k
Twitter followers
1.5 k
Twitter followers
3.3 k
Twitter followers
16.3 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
5
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
7
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
8
Number of tweets (last 30 days)
13
Number of tweets (last 30 days)
10
Number of tweets (last 30 days)
4
Number of tweets (last 30 days)
23
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
4
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
23.3
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
5.1
Average likes per tweet (last 30 days)
40.6
Average likes per tweet (last 30 days)
3.4
Average likes per tweet (last 30 days)
36
Average likes per tweet (last 30 days)
3
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
75%
Percentage of tweets with engagement (last 30 days)
69.23%
Percentage of tweets with engagement (last 30 days)
60%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
86.96%

Financial

Revenue (est.)
Revenue (est.)
$787.6m (FY, 2023)
Revenue (est.)
$340.6m (FY, 2022)
Revenue (est.)
$36.3m (FY, 2023)
Revenue (est.)
$434.2m (FY, 2023)
Revenue (est.)
$3.6m (FY, 2022)
Revenue (est.)
$1.2b (FY, 2023)
Revenue (est.)
$2.2m (FY, 2022)
Revenue (est.)
$240.7m (FY, 2023)
Revenue (est.)
$1.8b (FY, 2023)
Cost of goods
Cost of goods
$9.1m (FY, 2023)
Cost of goods
$294.5m (FY, 2022)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$150.3m (FY, 2023)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$268.2m (FY, 2023)
Gross profit
Gross profit
$778.5m (FY, 2023)
Gross profit
$33.2m (FY, 2022)
Gross profit
N/A
Gross profit
N/A
Gross profit
N/A
Gross profit
$1.1b (FY, 2023)
Gross profit
N/A
Gross profit
N/A
Gross profit
$1.6b (FY, 2023)
Net income
Net income
($366.3m) (FY, 2023)
Net income
($231.6m) (FY, 2022)
Net income
($481.2m) (FY, 2023)
Net income
($606.6m) (FY, 2023)
Net income
($266.6m) (FY, 2022)
Net income
($536m) (FY, 2023)
Net income
($311.9m) (FY, 2022)
Net income
($209.3m) (FY, 2023)
Net income
($440.2m) (FY, 2023)

Operating

Patents Issued
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
240 (FY, 2016)
Patents Issued
359 (FY, 2016)
Patents Issued
N/A
Phase I Trials Products
Phase I Trials Products
6 (FY, 2020)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
2 (FY, 2016)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
24 (FY, 2020)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
4 (FY, 2016)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
6 (FY, 2020)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
1 (FY, 2016)
Phase III Trials Products
N/A
Phase III Trials Products
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 200.1m
Total funding raised
$ 409m
Total funding raised
N/A
Total funding raised
$ 468.9m
Total funding raised
$ 147.1m
Total funding raised
$ 1.5b
For sources of this data, please see the company profile

View Company Profiles

Lannett
HQ
Trevose, US
Employees
560↓ 31% decrease

Lannett is a company that specializes in pharmaceutical product families.

View company
Intellia Therapeutics
HQ
Cambridge, US
Employees
270↑ 28% increase

Intellia is developing therapeutic products to help people with genetic diseases.

View company
Ultragenyx
HQ
Novato, US
Employees
1,311↑ 17% increase

Ultragenyx Pharmaceutical is a company that develops therapies for rare genetic diseases.

View company
Bluebird Bio
HQ
Somerville, US
Employees
323↓ 38% decrease

Bluebird Bio is a developer of gene therapies for severe genetic diseases.

View company